Patents by Inventor Christopher Ronald Sarko

Christopher Ronald Sarko has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds and compositions for the treatment of parasitic diseases
    Patent number: 11597733
    Abstract: The present invention provides a compound of formula (Ia) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, solid forms, combinations of pharmacologically active agents, pharmaceutical compositions and methods of using such compounds and solid forms thereof to treat or prevent parasitic diseases, for example malaria.
    Type: Grant
    Filed: October 21, 2020
    Date of Patent: March 7, 2023
    Assignee: Novartis AG
    Inventors: Nicole Alice Blaquiere, Richard Yichong Huang, Thomas Martin Kirrane, Jr., Andreas Kordikowski, Anne-Catherine Mata, Christopher Ronald Sarko, Benjamin Robert Taft, Grace Lamprecht Waldron, Fumiaki Yokokawa, Tingying Zhu
  • Inhibitors of TRPC6
    Patent number: 11485740
    Abstract: The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts therefore, wherein R1 to R6, A, U, V, W, X, Y, and Z are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: February 13, 2019
    Date of Patent: November 1, 2022
    Assignees: Boehringer Ingelheim International GmbH, Hydra Biosciences, LLC
    Inventors: Steven Brunette, Jianwen Cui, Michael D. Lowe, Christopher Ronald Sarko, Simon Surprenant, Michael Robert Turner, Xinyuan Wu, Lana Louise Smith Keenan, Thierry Bouyssou, Paul Nicklin
  • INHIBITORS OF TRPC6
    Publication number: 20210163449
    Abstract: The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 to R7, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: December 8, 2020
    Publication date: June 3, 2021
    Applicants: Boehringer Ingelheim International GmbH, Hydra Biosciences, LLC
    Inventors: Thierry Bouyssou, Dirk Gottschling, Niklas Heine, Lana Louise Smith Keenan, Michael D. Lowe, Hossein Razavi, Christopher Ronald Sarko, Simon Surprenant, Hidenori Takahashi, Michael Robert Turner, Xinyuan Wu
  • COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES
    Publication number: 20210115065
    Abstract: The present invention provides a compound of formula (Ia) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, solid forms, combinations of pharmacologically active agents, pharmaceutical compositions and methods of using such compounds and solid forms thereof to treat or prevent parasitic diseases, for example malaria.
    Type: Application
    Filed: October 21, 2020
    Publication date: April 22, 2021
    Inventors: Nicole Alice Blaquiere, Richard Yichong Huang, Thomas Martin Kirrane, JR., Andreas Kordikowski, Anne-Catherine Mata, Christopher Ronald Sarko, Benjamin Robert Taft, Grace Lamprecht Waldron, Fumiaki Yokokawa, Tingying Zhu
  • Inhibitors of TRPC6
    Patent number: 10889568
    Abstract: The invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R7, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: January 12, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Thierry Bouyssou, Dirk Gottschling, Niklas Heine, Lana Louise Smith Keenan, Michael D. Lowe, Hossein Razavi, Christopher Ronald Sarko, Simon Surprenant, Hidenori Takahashi, Michael Robert Turner, Xinyuan Wu
  • INHIBITORS OF TRPC6
    Publication number: 20200399282
    Abstract: The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts therefore, wherein R1 to R6, A, U, V, W, X, Y, and Z are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: February 13, 2019
    Publication date: December 24, 2020
    Inventors: Steven Brunette, Jianwen Cui, Michael D. Lowe, Christopher Ronald Sarko, Simon Surprenant, Michael Robert Turner, Xinyuan Wu, Lana Louise Smith Keenan, Thierry Bouyssou, Paul Nicklin
  • Inhibitors of TRPC6
    Patent number: 10800757
    Abstract: The invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R7, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: October 13, 2020
    Assignees: Boehringer Ingelheim International GmbH, Hydra Biosciences, LLC
    Inventors: Thierry Bouyssou, Dirk Gottschling, Niklas Heine, Lana Louise Smith Keenan, Michael D. Lowe, Hossein Razavi, Christopher Ronald Sarko, Simon Surprenant, Hidenori Takahashi, Michael Robert Turner, Xinyuan Wu
  • INHIBITORS OF TRPC6
    Publication number: 20190169167
    Abstract: The invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R7, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: October 25, 2018
    Publication date: June 6, 2019
    Inventors: Thierry Bouyssou, Dirk Gottschling, Niklas Heine, Lana Louise Smith Keenan, Michael D. Lowe, Hossein Razavi, Christopher Ronald Sarko, Simon Surprenant, Hidenori Takahashi, Michael Robert Turner, Xinyuan Wu
  • INHIBITORS OF TRPC6
    Publication number: 20190169168
    Abstract: The invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R7, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: October 25, 2018
    Publication date: June 6, 2019
    Inventors: Thierry Bouyssou, Dirk Gottschling, Niklas Heine, Lana Louise Smith Keenan, Michael D. Lowe, Hossein Razavi, Christopher Ronald Sarko, Simon Surprenant, Hidenori Takahashi, Michael Robert Turner, Xinyuan Wu
  • Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
    Patent number: 9353090
    Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R5, R6, R7, R8, R9, B, V, W, X, Y, Z and m are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: May 31, 2016
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Jehrod Burnett Brenneman, John David Ginn, Tamara Denise Hopkins, Michael D. Lowe, Christopher Ronald Sarko, John A. Westbrook, Maolin Yu, Zhonghua Zhang
  • HETEROCYCLIC CARBOXYLIC ACIDS AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE
    Publication number: 20160024059
    Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R5, R6, R7, R8, R9, B, V, W, X, Y, Z and m are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: July 21, 2015
    Publication date: January 28, 2016
    Inventors: Jehrod Burnett BRENNEMAN, John David GINN, Tamara Denise HOPKINS, MIchael D. LOWE, Christopher Ronald SARKO, John A. WESTBROOK, Maolin YU, Zhonghua ZHANG
  • Heterocyclic compounds containing an indole core
    Patent number: 9150577
    Abstract: Disclosed are novel compounds which inhibit RSK, methods of making such compounds and pharmaceutical compositions comprising such compounds. Also disclosed are methods of treating RSK2 regulated disorders using compounds of the invention.
    Type: Grant
    Filed: November 30, 2010
    Date of Patent: October 6, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Stephen J. Boyer, Donghong Amy Gao, Xin Guo, Thomas Martin Kirrane, Jr., Christopher Ronald Sarko, Roger John Snow, Fariba Soleymanzadeh, Yunlong Zhang
  • ANTICOAGULANT ANTIDOTES
    Publication number: 20140377265
    Abstract: The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants.
    Type: Application
    Filed: July 22, 2014
    Publication date: December 25, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Joanne VAN RYN, Keith CANADA, Robert COPENHAVER, Norbert HAUEL, Tobias LITZENBURGER, Christopher Ronald SARKO, Sanjaya SINGH, Alisa K. WATERMAN
  • Alkoxy pyrazoles as soluble guanylate cyclase activators
    Patent number: 8906904
    Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6 and R7 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: September 3, 2013
    Date of Patent: December 9, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Jehrod Burnett Brenneman, John Ginn, Michael D. Lowe, Christopher Ronald Sarko, Edward S. Tasber, Zhonghua Zhang
  • Anticoagulant antidotes comprising antibodies that bind dabigatran and/or related compounds and methods of use thereof
    Patent number: 8821871
    Abstract: The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants.
    Type: Grant
    Filed: March 28, 2012
    Date of Patent: September 2, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Joanne Van Ryn, Keith Canada, Robert Copenhaver, Norbert Hauel, Tobias Litzenburger, Christopher Ronald Sarko, Sanjaya Singh, Alisa K. Waterman
  • ALKOXY PYRAZOLES AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS
    Publication number: 20140073629
    Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6 and R7 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: September 3, 2013
    Publication date: March 13, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Jehrod Burnett BRENNEMAN, John GINN, Michael D. LOWE, Christopher Ronald SARKO, Edward S. TASBER, Zhonghua ZHANG
  • Serotonin 5-HT2B receptor inhibitors
    Patent number: 8609696
    Abstract: Disclosed are Serotonin 5-HT2B receptor inhibitors of the formula I. Also disclosed are methods of making and methods of using these compounds.
    Type: Grant
    Filed: December 14, 2009
    Date of Patent: December 17, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Derek Cogan, Neil Moss, Christopher Ronald Sarko, Samantha Jayne Bamford, Pui Leng Loke, Heather Tye, Mark Whittaker
  • Soluble guanylate cyclase activators
    Patent number: 8569339
    Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, A and B are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: March 8, 2012
    Date of Patent: October 29, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Jehrod Burnett Brenneman, John D. Huber, Brian Christopher Raudenbush, Christopher Ronald Sarko
  • Alkoxy pyrazoles as soluble guanylate cyclase activators
    Patent number: RE46886
    Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6 and R7 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: June 5, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Jehrod Burnett Brenneman, John Ginn, Michael D. Lowe, Christopher Ronald Sarko, Edward S. Tasber, Zhonghua Zhang
  • Inhibitors of TRPC6
    Patent number: RE49699
    Abstract: The invention related to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R2, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: May 28, 2021
    Date of Patent: October 17, 2023
    Assignees: Boehringer Ingelheim International GmbH, Hydra Biosciences, LLC
    Inventors: Thierry Bouyssou, Dirk Gottschling, Niklas Heine, Lana Louise Smith Keenan, Michael D. Lowe, Hossein Razavi, Christopher Ronald Sarko, Simon Surprenant, Hidenori Takahashi, Michael Robert Turner, Xinyuan Wu